Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 40, Issue 1, 2017, Pages 47-52

  Cushen, Samantha J ^a   Power, Derek G ^b   Teo, Min Y ^d   MacEneaney, Peter ^c   Maher, Michael M ^c   McDermott, Ray ^d   O'Sullivan, Kathleen ^a   Ryan, Aoife M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c MERCY UNIVERSITY HOSPITAL   (Ireland)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Dose limiting toxicity; Fat free mass; Renal cell carcinoma; Sarcopenia; Sunitinib

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGE; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE; DOSE LIMITING TOXICITY; DRUG DOSE REDUCTION; DRUG TOXICITY; DRUG WITHDRAWAL; FAT FREE MASS; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; IMAGING SOFTWARE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; NAUSEA; OBESITY; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOPENIA; SEX DIFFERENCE; SKELETAL MUSCLE; STOMATITIS; SUBCUTANEOUS FAT; UNDERWEIGHT; VOMITING; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY COMPOSITION; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYRROLES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896691871     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000061     Document Type: Article

References (36)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
2. Gore ME, Bellmunt J, Eisen T, et al. Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur J Cancer. 2012;48:1038-1047.
3. Ibrahim EM, Kazkaz GA, Abouelkhair KM, et al. Sunitinib adverse events in metastatic renal cell carcinoma: a metaanalysis. Int J Clin Oncol. 2013;18:1060-1069.
4. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet. 2007;370:2071-2073.
5. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-3268.
6. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920-2926.
7. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a populationbased study. Lancet Oncol. 2008;9:629-635.
8. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21: 1594-1598.
9. Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebocontrolled study. J Clin Oncol. 2010;28:1054-10560.
10. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early doselimiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563.
11. Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67:93-101.
12. Stanisavljevic NS, Marisavljevic DZ. Weight and body composition changes during R-CHOP chemotherapy in patients with non- Hodgkin's lymphoma and their impact on dose intensity and toxicity. J BUON. 2010;15:290-296.
13. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91:1133S-1137S.
14. Morgan D, Bray K. Lean body mass as a predictor of drug dosage. Clin Pharmacokinet. 1994;26:292-307.
15. Nelson KM, Weinsier RL, Long CL, et al. Prediction of resting energy expenditure from fat-free mass and fat mass. Am J Clin Nutr. 1992;56:848-856.
16. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457-3465.
17. Sugiyama M, Fujita K, Murayama N, et al. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. Drug Metab Dispos. 2011;39:757-762.
18. Geraghty EM, Boone JM. Determination of height, weight, body mass index, and body surface area with a single abdominal CT image. Radiology. 2003;228:857-863.
19. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594-1598.
20. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997-1006.
21. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
22. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108:1034-1041.
23. Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973-6979.
24. Tang PA, Heng DY, Choueiri TK. Impact of body composition on clinical outcomes in metastatic renal cell cancer. Oncologist. 2010;16:1484-1486.
25. Antoun S, Lanoy E, Lacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119:3377-3384.
26. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599-603.
27. Thibault R, Genton L, Pichard C. Body composition: why, when and for who? Clin Nutr. 2012;31:435-447.
28. van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99:259-265.
29. Gurney HP, Ackland S, Gebski V, et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol. 1998;16: 2299-2304.
30. Mathijssen RHJ, de Jong FA, Loos WJ, et al. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: does it make a difference? Oncologist. 2007;12: 913-923.
31. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci. 2001;6:D164-D174.
32. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo controlled study. Clin Endocrinol Metab. 2013;98:2401-2408.
33. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early doselimiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563.
34. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
35. Richards CH, Roxburgh CSD, MacMillan M, et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7:e41883.
36. Prado CM, Antoun S, Sawyer MB, et al. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care. 2011;14:250-254.